Alterity Sale Purchase Of Stock vs Issuance Of Capital Stock Analysis
ATHE Stock | USD 1.09 0.03 2.83% |
Alterity Therapeutics financial indicator trend analysis is way more than just evaluating Alterity Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alterity Therapeutics is a good investment. Please check the relationship between Alterity Therapeutics Sale Purchase Of Stock and its Issuance Of Capital Stock accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alterity Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.
Sale Purchase Of Stock vs Issuance Of Capital Stock
Sale Purchase Of Stock vs Issuance Of Capital Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alterity Therapeutics Sale Purchase Of Stock account and Issuance Of Capital Stock. At this time, the significance of the direction appears to have no relationship.
The correlation between Alterity Therapeutics' Sale Purchase Of Stock and Issuance Of Capital Stock is 0.01. Overlapping area represents the amount of variation of Sale Purchase Of Stock that can explain the historical movement of Issuance Of Capital Stock in the same time period over historical financial statements of Alterity Therapeutics, assuming nothing else is changed. The correlation between historical values of Alterity Therapeutics' Sale Purchase Of Stock and Issuance Of Capital Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Sale Purchase Of Stock of Alterity Therapeutics are associated (or correlated) with its Issuance Of Capital Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Issuance Of Capital Stock has no effect on the direction of Sale Purchase Of Stock i.e., Alterity Therapeutics' Sale Purchase Of Stock and Issuance Of Capital Stock go up and down completely randomly.
Correlation Coefficient | 0.01 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Sale Purchase Of Stock
Issuance Of Capital Stock
Most indicators from Alterity Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alterity Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alterity Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.The current year's Issuance Of Capital Stock is expected to grow to about 11.2 M, whereas Selling General Administrative is forecasted to decline to about 3.5 M.
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 54.2K | 102.3K | 35.3K | 33.6K | Research Development | 14.7M | 13.2M | 18.6M | 19.6M |
Alterity Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Alterity Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Alterity Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 13.3M | 33.6M | 41.4M | 27.3M | 19.2M | 21.8M | |
Total Stockholder Equity | 10.5M | 30.5M | 35.5M | 22.8M | 13.8M | 19.2M | |
Net Debt | (9.2M) | (28.0M) | (34.7M) | (15.6M) | (12.5M) | (13.1M) | |
Cash | 9.2M | 28.1M | 34.8M | 15.8M | 12.6M | 15.7M | |
Cash And Short Term Investments | 9.2M | 28.1M | 34.8M | 15.8M | 12.6M | 15.7M | |
Common Stock Shares Outstanding | 1.5M | 2.8M | 4.0M | 4.0M | 6.1M | 6.4M | |
Liabilities And Stockholders Equity | 13.3M | 33.6M | 41.4M | 27.3M | 19.2M | 21.8M | |
Other Stockholder Equity | (4.3M) | (20.8M) | (22.0M) | 4.0M | 4.8M | 8.7M | |
Total Current Assets | 13.2M | 33.5M | 41.1M | 27.0M | 19.0M | 18.7M | |
Common Stock | 160.7M | 197.4M | 213.8M | 214.0M | 223.2M | 114.0M | |
Other Current Liab | 1.2M | 1.6M | 3.1M | 2.5M | 4.7M | 4.9M | |
Total Current Liabilities | 2.7M | 3.1M | 5.8M | 4.4M | 5.4M | 2.8M | |
Property Plant And Equipment Net | 71.4K | 96.8K | 218.5K | 268.9K | 186.9K | 105.7K | |
Retained Earnings | (151.0M) | (169.7M) | (181.9M) | (195.1M) | (214.2M) | (203.5M) | |
Accounts Payable | 954.0K | 1.4M | 2.6M | 1.7M | 581.1K | 552.1K | |
Non Current Assets Total | 71.4K | 96.8K | 218.5K | 268.9K | 186.9K | 177.5K | |
Non Currrent Assets Other | (49.3K) | (96.8K) | (218.5K) | (268.9K) | (242.0K) | (229.9K) | |
Net Receivables | 3.5M | 4.1M | 4.7M | 8.6M | 4.0M | 2.9M | |
Inventory | 567.9K | 2.0 | 1.6M | 2.6M | (22.4K) | (21.3K) | |
Other Current Assets | 10.3K | 1.2M | 1.7M | 2.6M | 2.4M | 2.5M | |
Total Liab | 2.8M | 3.1M | 5.9M | 4.5M | 5.4M | 2.9M | |
Common Stock Total Equity | 143.9M | 156.6M | 160.7M | 197.4M | 227.1M | 128.1M | |
Non Current Liabilities Total | 42.4K | 47.7K | 73.6K | 122.7K | 51.9K | 68.3K | |
Property Plant And Equipment Gross | 71.4K | 96.8K | 733.1K | 728.8K | 619.1K | 650.0K | |
Accumulated Other Comprehensive Income | 866.1K | 2.8M | 3.6M | 4.0M | 4.8M | 5.0M | |
Short Long Term Debt Total | 33.7K | 65.6K | 117.5K | 210.4K | 159.0K | 131.6K | |
Short Term Debt | 32.9K | 27.7K | 57.6K | 107.2K | 107.1K | 105.8K | |
Other Assets | (0.53) | 0.03 | (0.48) | 1.0 | 0.9 | 0.86 | |
Other Liab | 41.5K | 9.8K | 13.8K | 19.5K | 22.4K | 15.0K | |
Net Tangible Assets | 7.2M | 30.5M | 35.5M | 22.8M | 26.2M | 24.6M | |
Capital Lease Obligations | 33.7K | 65.6K | 117.5K | 210.4K | 159.0K | 167.0K | |
Property Plant Equipment | 71.4K | 96.8K | 218.5K | 268.9K | 309.2K | 324.7K | |
Net Invested Capital | 7.2M | 30.5M | 35.5M | 22.8M | 13.8M | 22.8M | |
Net Working Capital | 7.1M | 30.4M | 35.3M | 22.7M | 13.7M | 22.7M | |
Capital Stock | 160.7M | 197.4M | 213.8M | 214.0M | 223.2M | 213.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Alterity Therapeutics is a strong investment it is important to analyze Alterity Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alterity Therapeutics' future performance. For an informed investment choice regarding Alterity Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alterity Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alterity Therapeutics. If investors know Alterity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alterity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share 0.6 | Quarterly Revenue Growth 0.384 | Return On Assets (0.53) | Return On Equity (1.04) |
The market value of Alterity Therapeutics is measured differently than its book value, which is the value of Alterity that is recorded on the company's balance sheet. Investors also form their own opinion of Alterity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alterity Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alterity Therapeutics' market value can be influenced by many factors that don't directly affect Alterity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alterity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alterity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alterity Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.